Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-08-04
2009-10-06
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254010, C514S254050, C544S295000, C544S357000, C544S363000, C544S364000, C544S365000, C544S368000, C544S369000, C544S370000, C544S371000, C544S372000, C546S208000, C546S221000, C546S278400, C548S204000, C548S324100, C548S518000, C548S556000, C548S452000, C548S512000
Reexamination Certificate
active
07598250
ABSTRACT:
Disclosed are novel compounds of the formulaor a pharmaceutically acceptable salt or solvate thereof, whereinR1isX is —O—, —C(R14)2— or —N(R)—;Z is —C(R14)2— or —N(R)—;t is 0, 1, 2 or 3;each R and R2is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl;each R14is H, alkyl, alkenyl, alkynyl, halo, —CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, —OR35, —N(R24)(R25) or —SR35;R41is alkyl, cycloalkyl, —SO2(alkyl), —C(O)-alkyl, —C(O)-cycloalkyl or -alkyl-NH—C(O)CH3;and the remaining variables are as defined in the specification.Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I.Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.
REFERENCES:
patent: 6683091 (2004-01-01), Asberom et al.
patent: WO 95/18104 (1995-06-01), None
patent: WO 0007995 (2000-02-01), None
patent: WO 0050391 (2000-08-01), None
patent: WO 0202505 (2002-01-01), None
patent: WO 0202506 (2002-01-01), None
patent: WO 0202512 (2002-01-01), None
patent: WO 0202518 (2002-01-01), None
patent: WO 0202520 (2002-01-01), None
patent: WO 02/02520 (2002-10-01), None
patent: WO 02088101 (2002-11-01), None
patent: WO 03013527 (2003-02-01), None
patent: WO 03018543 (2003-03-01), None
patent: WO 03066592 (2003-08-01), None
Vippagunta et al. Advanced Drug Delivery Reviews, vol. 48, p. 3-26 (2001).
Hom, Expert Opin.Ther. Patents, vol. 17,p. 737-740 (2007).
McGaughey et al. Expert Opin.Drug Discov. vol. 2 (8),pp. 1129-1138 (2007).
Melnikova, Nature Reviews Drug Discovery, vol. 6, p. 341-342 (2007).
Philip L. Gould, Salt Selection for Basic Drugs,International Journal of Pharmaceutics, 33(1986) 201-217.
George R. Pettit, et al., The Dolastatins; 18: Stereospecific Synthesis of Dolaproine,Synthesis, (1996) 719-725.
Ugo Pfeiffer, et al., A Short Synthesis of 4-Imidazolidinone,Liebigs Ann. Chem., (1988) 993-995.
Bruno Bellier, et al., Synthesis and Biological Properties of New Constrained CCK-B Antagonists: Discrimination of Two Affinity States of the CCK-B Receptor on Transfected CHO Cells,J. Med. Chem., (1997) 40:3947-3956.
Thomas R. Webb, et al., Conformationally Restricted Arginine Analogues,J. Org. Chem., (1991) 56:3009-3016.
Stephen Hanessian, et al., The Power of Visual Imagery in Synthesis Planning. Stereocontrolled Approaches to CGP-60536B, a Potent Renin Inhibitor,J. Org. Chem., (2002) 67:4261-4274.
Samuel Chackalamannil, et al., Total Synthesis of (+)-Himbacine and (+)-Himbeline,J. Org. Chem. (1999) 64:1932-1940.
Christoph Hock, et al., Generation of Antibodies Specific for β-amyloidby Vaccination of Patients with Alzheimer Disease,Nature Medicine, (2002) 8:1270-1275.
Toshimasa Itoh et al., Asymmetric Synthesis of (−)-Adaline,Organic Letters, (2002) 4:2469-2472.
Christopher J. Dinsmore, et al., 3,8-Diazabicyclo[3.2.1]octan-2-one Peptide Mimetics: Synthesis of a Conformationally Restricted Inhibitor of Farnesyltransferase,Organic Letters, (2001) 3:865-868.
Lawrence I. Kruse, et al., Multisubstrate Inhibitors of Dopamine β-Hydroxylase. 2.1Structure-Activity Relationships at the Phenethylamine Binding Site,J. Med. Chem., (1987) 30:486-494.
Zhenping Tian et al., An Efficient Scalable Process for the Synthesis of N-Boc-2-tert-butyldimethylsiloxypyrrole,Organic Process Research&Development, (2002) 6:416-418.
Gordon Lowe et al., Amino Acid Bearing Nucleobases for the Synthesis of Novel Peptide Nucleic Acids,J. Chem. Soc., Perkin Trans.1, (1997) 539-546.
Stephen M. Berge, et al., Pharmaceutical Salts,Journal of Pharmaceutical Sciences(1977) 66:1-19.
International Search Report for International Application No. PCT/US2004/025018, mailed Aug. 22, 2005, (5 pages).
Cumming Jared N.
Guo Tao
Hobbs Douglas W.
Huang Ying
Iserloh Ulrich
Bernhardt Emily
MacMillan Keith D.
Schering Corporation
LandOfFree
Cyclic amine BACE-1 inhibitors having a heterocyclic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic amine BACE-1 inhibitors having a heterocyclic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic amine BACE-1 inhibitors having a heterocyclic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4064341